Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334661 | 0.92 | DRD2 (0.33) | DRD2SIGMAR1OPRL1OPRM1HSD11B1 | |
| SCHEMBL4329852 | 0.92 | DRD2 (0.33) | DRD2SIGMAR1OPRL1OPRM1HSD11B1 | |
| SCHEMBL4319333 | 0.89 | SIGMAR1 (0.40) | DRD2SIGMAR1OPRL1OPRM1GRIN2D | |
| SCHEMBL4318605 | 0.86 | OPRL1 (0.35) | OPRL1OPRM1HSD11B1EGLN1 | |
| SCHEMBL4323012 | 0.80 | DRD2 (0.39) | DRD2SIGMAR1OPRL1OPRM1HSD11B1 | |
| SCHEMBL4325132 | 0.79 | DRD2 (0.41) | DRD2SIGMAR1OPRL1OPRM1GRIN2D | |
| SCHEMBL4335931 | 0.75 | PDE3B (0.34) | DRD2SIGMAR1OPRL1OPRM1HSD11B1 | |
| SCHEMBL4328880 | 0.71 | CXCR3 (0.38) | DRD2OPRL1HSD11B1 | |
| SCHEMBL4321309 | 0.70 | DRD2 (0.37) | DRD2SIGMAR1OPRL1OPRM1 | |
| SCHEMBL13914043 | 0.70 | SIGMAR1 (0.39) | SIGMAR1HSD11B1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | DRD2 121/4885SIGMAR1 247/4885OPRL1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.